Show Summary Details
Page of

Non-ischaemic cardiomyopathy 

Non-ischaemic cardiomyopathy
Non-ischaemic cardiomyopathy

Dr Julian Ormerod

and Michael Frenneaux

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 23 January 2021

From the glimpses provided in this chapter it will be clear that there have been huge advances in our understanding of the aetiological basis for the cardiomyopathies— particularly the molecular genetics—and of the pathophysiology of these disorders. However, it must be acknowledged that, thus far, these exciting data have not translated into specific therapies. Our recent paper demonstrating that the metabolic modulator perhexiline partially corrects cardiac energetic impairment in patients with hypertrophic cardiomyopathy, and that this translates into improved symptoms and exercise capacity, may be a forerunner of such therapeutic translation.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.